Discovery of innovative peptide medicines leveraging its proprietary Peptide Discovery Platform System
PeptiDream is leading the translation of macrocyclic peptides into a whole new class of innovative medicines to address unmet medical needs and improve the quality of life of patients worldwide. Leveraging its proprietary Peptide Discovery Platform System (PDPS) technology, we aim to discover and develop a broad and diverse pipeline of peptide therapeutics. In its radiopharmaceutical business, PeptiDream group markets and sells a number of approved radiopharmaceuticals in Japan through its wholly-owned subsidiary PDRadiopharma.
Drug Discovery/Drug Discovery Support
- Pharmaceuticals